Palosis 0.5 mg (Tablet)

Unit Price: ৳ 20.00 (2 x 10: ৳ 400.00)
Strip Price: ৳ 200.00

Medicine Details

Category Details
Generic Palonosetron
Company Eskayef pharmaceuticals ltd
Also available as
Palosis 05 mg capsule Palosis 0075 mg injection Palosis 025 mg injection

Title

  • Palosis Anti-emetic Tablet

Categories

  • Medicine
  • Healthcare
  • Pharmaceuticals

Description

  • Palosis is indicated for the treatment of acute and delayed nausea and vomiting, uncontrolled nausea and vomiting, chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), post-operative & post-discharge nausea and vomiting (PONV & PDNV). It is a 5-HT3 receptor antagonist with linear dose-proportional pharmacokinetics, exhibiting a longer half-life and greater 5-HT3 receptor binding affinity. Adult tablet dosage is 0.5 mg daily, while adult IV dosage is a single IV dose of 0.075 mg administered over 10 seconds. It is safe to administer with corticosteroids, analgesics, antiemetics/antinauseants, antispasmodics, and anticholinergic agents. Side effects may include headaches and constipation. It falls under pregnancy category 'B' and its pregnancy and lactation effects are not fully known. No dosage adjustment is recommended for use in elderly patients, children, and patients with impaired renal and hepatic function. Overdose effects should be managed with supportive care. It belongs to the therapeutic class of anti-emetic drugs and should be stored in a cool & dry place, protected from light.

Dimensions

  • 2cm x 1.5cm x 0.5cm

Color options

  • White

Functions

  • Treatment of acute and delayed nausea and vomiting
  • 5-HT3 receptor antagonist
  • Linear dose-proportional pharmacokinetics
  • Greater 5-HT3 receptor binding affinity

Materials

  • Active ingredient: Palonosetron
  • Inactive ingredients: Fillers, binders

Technical specifications

  • Adult tablet dosage: 0.5 mg daily
  • Adult IV dosage: A single IV dose of 0.075 mg administered over 10 seconds
  • Volume of distribution: Approximately 6.9-7.9 L/kg
  • Approximately 62% bound to plasma proteins
  • Approximately 40% of the drug is metabolized via the kidney, 50% by liver CYP2D6, CYP3A4, and CYP1A2 isoenzymes
  • Approximately 40% of the drug is excreted as unchanged drug in the urine after 144 hours
  • Total body clearance: 160±35 ml/h/kg
  • Renal clearance: 66.5±18.2 ml/h/kg
  • Half-life: 40 hours

Design elements

  • Tablet form
  • IV solution

Usability features

  • Safe to administer with corticosteroids, analgesics, antiemetics/antinauseants, antispasmodics, and anticholinergic agents

Dosage and administration

  • Adult tablet dosage: 0.5 mg daily
  • Adult IV dosage: A single IV dose of 0.075 mg administered over 10 seconds
  • Children dosage: A single IV dose at 20 mcg/kg body weight, with a maximum dose of 1.5 mg
  • Administration timing for various conditions: 1 hour prior to the start of chemotherapy, 30 minutes before the start of chemotherapy, 30 minutes before each week of radiation fraction, immediately before induction of anesthesia

Interaction

  • Safe administration with corticosteroids, analgesics, antiemetics/antinauseants, antispasmodics, and anticholinergic agents
  • No significant pharmacokinetic interactions with metoclopramide
  • Not an inhibitor or inducer of various CYP enzymes

Contraindications

  • Hypersensitivity to Palonosetron or any of its components

Side effects

  • Headaches
  • Constipation

Pregnancy and lactation

  • Pregnancy category 'B'
  • Not fully known whether Palonosetron is excreted in breast milk

Use in special populations

  • No dosage adjustment recommended in elderly patients >65 years of age
  • No dosage adjustment recommended in patients with impaired renal and hepatic function

Overdose effects

  • No known antidote to Palosis
  • Should be managed with supportive care

Storage conditions

  • Store in a cool & dry place, protected from light

Therapeutic class

  • Anti-emetic drugs

Related Brands